BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 12211426)

  • 1. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.
    Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP
    J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The skeletal structure of insulin-like growth factor I-deficient mice.
    Bikle D; Majumdar S; Laib A; Powell-Braxton L; Rosen C; Beamer W; Nauman E; Leary C; Halloran B
    J Bone Miner Res; 2001 Dec; 16(12):2320-9. PubMed ID: 11760848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
    Hilal G; Massicotte F; Martel-Pelletier J; Fernandes JC; Pelletier JP; Lajeunesse D
    J Bone Miner Res; 2001 Apr; 16(4):713-21. PubMed ID: 11315999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
    Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program.
    Rosen CJ; Ackert-Bicknell CL; Adamo ML; Shultz KL; Rubin J; Donahue LR; Horton LG; Delahunty KM; Beamer WG; Sipos J; Clemmons D; Nelson T; Bouxsein ML; Horowitz M
    Bone; 2004 Nov; 35(5):1046-58. PubMed ID: 15542029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.
    Ishizuya T; Yokose S; Hori M; Noda T; Suda T; Yoshiki S; Yamaguchi A
    J Clin Invest; 1997 Jun; 99(12):2961-70. PubMed ID: 9185520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging impairs IGF-I receptor activation and induces skeletal resistance to IGF-I.
    Cao JJ; Kurimoto P; Boudignon B; Rosen C; Lima F; Halloran BP
    J Bone Miner Res; 2007 Aug; 22(8):1271-9. PubMed ID: 17488198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I.
    Kostenuik PJ; Harris J; Halloran BP; Turner RT; Morey-Holton ER; Bikle DD
    J Bone Miner Res; 1999 Jan; 14(1):21-31. PubMed ID: 9893062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
    Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
    J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
    Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
    Locklin RM; Khosla S; Turner RT; Riggs BL
    J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice.
    Yamaguchi M; Ogata N; Shinoda Y; Akune T; Kamekura S; Terauchi Y; Kadowaki T; Hoshi K; Chung UI; Nakamura K; Kawaguchi H
    Endocrinology; 2005 Jun; 146(6):2620-8. PubMed ID: 15718274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
    Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
    Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
    Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
    J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
    Wang L; Quarles LD; Spurney RF
    J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
    Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
    J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
    Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
    Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic alcohol consumption during male rat adolescence impairs skeletal development through effects on osteoblast gene expression, bone mineral density, and bone strength.
    Wezeman FH; Emanuele MA; Emanuele NV; Moskal SF; Woods M; Suri M; Steiner J; LaPaglia N
    Alcohol Clin Exp Res; 1999 Sep; 23(9):1534-42. PubMed ID: 10512321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein (PTH/PTHrP) receptor in bone development.
    Kondo H; Ohyama T; Ohya K; Kasugai S
    J Bone Miner Res; 1997 Dec; 12(12):2089-97. PubMed ID: 9421242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.